GLAUKOS Corp (GKOS) · Oct 28, 2026 · Earnings
Beat — Revenue $211.0M vs ~$168.0M consensus; diluted EPS $0.03 vs ~$(0.10) consensus
Glaukos earnings decisively beat expectations, with record sales, sharply higher 2026 guidance, and a preliminary $1 billion 2027 revenue target.
Glaukos is in a commercialization ramp built around iDose TR for glaucoma and Epioxa for corneal disease; recent operating context pointed to rising iDose utilization and an Epioxa transition from Photrexa as the main growth drivers. This quarter says that ramp is arriving faster than the market expected.
| Metric | Q3 2026 | Comparison / expectation |
|---|---|---|
| Net sales | $211.0M | $133.5M in Q3 2025; ~$168.0M consensus |
| Diluted GAAP EPS | $0.03 | $(0.28) in Q3 2025; ~$(0.10) consensus |
| Non-GAAP diluted EPS | $0.47 | $(0.16) in Q3 2025 |
| Gross margin | 85.2% | 78.4% in Q3 2025 |
| 2026 net sales guidance | $775M–$785M | Raised from $680M–$700M |
| Preliminary 2027 net sales guidance | $1.0B | Newly introduced |
The operating beat is unusually large. Revenue grew 58% year over year and came in about $43 million above the published consensus of $168.04 million; GAAP EPS also swung from an expected loss to a profit. The company’s own product areas were both contributing: U.S. Glaucoma sales reached $118.6 million, up 47%, while Corneal Health reached $59.0 million, up 154%.
This is more than a revenue beat because the margin profile improved at the same time. GAAP gross margin expanded to approximately 85% from 78% a year ago, while operating income turned positive at $0.8 million from a $16.4 million loss. The adjusted result was stronger at $27.3 million of operating income, but the reported profit improvement still matters because it shows the growth is beginning to absorb the company’s heavy commercial investment.
Management materially reset the growth path upward. Full-year 2026 revenue guidance rose to $775 million–$785 million from $680 million–$700 million, implying a roughly $95 million midpoint increase. The new preliminary 2027 target of $1 billion is the bigger signal: it frames the current iDose TR and Epioxa ramp as a durable commercial build rather than a one-quarter surge.
The balance sheet gives the company room to keep investing. Cash, short-term investments, and restricted cash totaled approximately $339.8 million at quarter-end, and the company reported no debt. That reduces the immediate need to fund the launch through borrowing or equity issuance, although the filing does not provide cash-flow detail sufficient to judge how much of the quarter’s cash increase came from operations.
Bottom line: This was a clear upside reset, not merely an in-line quarter: demand beat expectations by a wide margin, profitability improved, and management raised the near-term outlook while introducing a $1 billion 2027 target. The key business question now shifts from whether the launch is working to how consistently Glaukos can scale it through 2027.
Q4 report and 2027 sales execution against $1 billion target
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!